Cas:483-66-9 Sphondin manufacturer & supplier

Chemical Name:Sphondin

CAS.NO:483-66-9

Synonyms:6-Methoxy-2H-furo[2,3-h]chromen-2-one;Sfondin;6-Methoxyfuro[2,3-h]chromen-2-one;2H-Furo[2,3-h]-1-benzopyran-2-one, 6-methoxy-;6-Methoxy-2H-furo(2,3-h)-1-benzopyran-2-one;Sphondin;6-Methoxy-furano-<2′,3′-7,8>cumarin,Sphondin

Molecular Formula:C₁₂H₈O₄

Molecular Weight:216.189

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:413.0±45.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.635

PSA:52.58000

Exact Mass:216.042252

LogP:1.83

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-Methoxy-2H-furo[2,3-h]chromen-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,cumarin,Sphondin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Methoxy-2H-furo[2,3-h]chromen-2-one Use and application,2H-Furo[2,3-h]-1-benzopyran-2-one, 6-methoxy- technical grade,usp/ep/jp grade.

Related News: Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. Sphondin manufacturer The European Medicines Agency did not say how many shots were affected, but Reuters has reported it involves millions of doses, making it harder for J&J to meet a target of delivering 55 million to Europe by end of June. Sphondin supplier A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. Sphondin vendor Like Altasciences, Alira has also placed an emphasis on the preclinical setting in recent months with its March hire of Nikole Siegmund as vice president of preclinical development. Sphondin factory While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added.